CHRS MEXC RealStocks
Own real CHRS shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 11:02:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Coherus Oncology, Inc. (CHRS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.53, with a market capitalization of $83.22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.51 to $2.62. This page covers its latest market performance, valuation, price trends and company information.
$83.22M | |
$0.53 | |
$0.53 | |
$0.53 | |
$0.54 | |
360.00 | |
1.65M | |
-- | |
$2.62 | |
$0.51 | |
-- | |
-- |
Coherus Oncology, Inc. (CHRS) is trading at $0.53 in pre-market trading as of 2026-11-13 09:17:00, down 0.84% ($0.00) from the previous close of $0.54
Pre-market trading shows how investors are pricing CHRS before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Coherus Oncology, Inc. (CHRS) moved from $0.75 to $0.53, representing a decline of 28.70% ($0.21).
The stock traded between $0.51 and $0.86 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.81 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.1%
CHRS is currently trading at $0.53, placing it 1.1% of the way from its 52-week low of $0.51 to its 52-week high of $2.62. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 145 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Coherus Oncology, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Coherus Oncology, Inc. (CHRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CHRS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CHRS shares and USD.
CHRS Shares to USD
1.00 CHRS shares = 0.534 USD
Calculations are estimates based on the latest available price and are for reference only.